Alterations of the Renin-angiotensin-aldosterone System in sEptic Shock

ConditionSeptic Shock
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Septic shock is a common and life-threatening condition associated with an in-hospital mortality rate exceeding 40%. The symptomatic management of septic shock relies primarily on vasopressor therapy, particularly norepinephrine. However, the use of high doses of norepinephrine may lead to adverse effects, prompting the search for alternative therapeutic strategies, including angiotensin II, which has recently been investigated as an adjunctive vasopressor.

Indeed, alterations of the renin-angiotensin-aldosterone system (RAAS), particularly a relative deficiency of angiotensin II, have been hypothesized to occur during septic shock. However, to date, no human study has used gold-standard techniques for measuring RAAS peptides to confirm this hypothesis.

Furthermore, it remains unclear whether these alterations are specific to septic shock or may also be observed in less severe infections (sepsis) or in other forms of circulatory failure, such as cardiogenic shock.

Eligibility criteria

Qualifiers

Proven or suspected infection.

Persistent arterial hypotension requiring norepinephrine administration to maintain a mean arterial pressure above 65 mmHg despite adequate fluid resuscitation.

Hyperlactatemia > 2 mmol/L.

Proven or suspected infection.

Disqualifiers

Patients deprived of liberty by judicial or administrative decision.

Patients admitted to the intensive care unit for more than 48 hours.

Patients previously enrolled in an interventional study with overlapping follow-up.

Patients benefiting from State Medical Aid (AME).

Trial design

Treatments tested in this trial

  • Collection of fluid samples

Treatment groups

320 Participants
are divided into 3 treatment groups

Locations

This trial has no locations